What Does iTeos Therapeutics Do?

Total employees192
HeadquartersCambridge
Founded2011

iTeos Therapeutics SA (NASDAQ: ITOS) is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The company is dedicated to transforming the treatment of cancer by designing and developing therapies that aim to activate and restore the immune system's ability to recognize and fight cancer. Their pipeline includes novel drug candidates targeting key immune checkpoints and pathways, such as EOS-448 (anti-TIGIT antibody) and EOS-984 (adenosine A2A receptor antagonist).

Where Is iTeos Therapeutics's Headquarters?

HQ Function

The Cambridge headquarters serves as the global operational and strategic hub, overseeing corporate strategy, business development, clinical operations management for US and global trials, investor relations, and general administration.

Notable Features:

Situated in the vibrant Kendall Square/East Cambridge biotech ecosystem, providing proximity to leading research institutions, collaborators, and a rich talent pool. The office is likely modern and designed to facilitate collaboration.

Work Culture:

The work culture is characterized by a strong focus on scientific innovation, collaboration, and a patient-centric approach. As a clinical-stage biotech, it's likely fast-paced and results-driven, with a commitment to advancing cancer therapies.

HQ Significance:

The US headquarters is critical for iTeos's engagement with the North American financial markets, regulatory bodies (FDA), clinical trial sites, and the broader US biotech community. Its location underscores the company's global ambitions and its focus on cutting-edge science.

Values Reflected in HQ: The choice of Cambridge for its global headquarters reflects iTeos's commitment to scientific excellence, innovation, access to top talent, and collaboration within the leading global biotech cluster.

Location:

iTeos Therapeutics operates with a significant global footprint, anchored by its global headquarters in Cambridge, MA, USA, and its research and discovery center in Louvain-la-Neuve, Belgium. The company manages global clinical trials across North America, Europe, and potentially other regions, collaborates with international research institutions, and engages in global business development activities to advance its immuno-oncology pipeline worldwide.

Street Address:

955 Massachusetts Avenue, Suite 201

City:

Cambridge

State/Province:

MA

Country:

USA

Where Else Does iTeos Therapeutics Operate Around the World?

Louvain-la-Neuve, Belgium

Address: Rue des Waides 8, 1348 Louvain-la-Neuve, Belgium

Acts as the hub for European research and development activities, leveraging the strong scientific environment in Belgium and Europe. It's foundational to the company's origins and ongoing discovery efforts.

Buying Intent Signals for iTeos Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading iTeos Therapeutics? Meet the Executive Team

As of April 2025, iTeos Therapeutics' leadership includes:

Michel Detheux, Ph.D. - President and Chief Executive Officer
Matthew Gall, MBA - Chief Financial Officer
Joanne Jenkins Lager, M.D. - Chief Medical Officer
Yvonne C. McArthur, Ph.D. - Chief Scientific Officer
David Hall, Ph.D. - Chief Business Officer
Philippe Van Trappen, M.D., Ph.D. - Head of Clinical Development
Robert Lechleider, M.D. - Head of Translational Medicine

Who's Investing in iTeos Therapeutics?

iTeos Therapeutics has been backed by several prominent investors over the years, including:

MPM Capital
RA Capital Management
Boxer Capital (Tavistock Group)
Fund+
Janus Henderson Investors
HBM Healthcare Investments
VIVES Louvain Technology Fund
SRIW (Société Régionale d'Investissement de Wallonie)

What Leadership Changes Has iTeos Therapeutics Seen Recently?

Hire1
Exits0

Over the past 12 months (mid-2023 to mid-2024), iTeos Therapeutics strengthened its leadership by appointing a new Chief Business Officer. No major executive departures were publicly announced during this period.

New Appointments:

David Hall, Ph.D., David Hall, Ph.D., appointed as Chief Business Officer to lead the company's business development, licensing, and strategic partnership efforts.

What Technology (Tech Stack) Is Used byiTeos Therapeutics?

Discover the tools iTeos Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

iTeos Therapeutics Email Formats and Examples

iTeos Therapeutics SA primarily utilizes a common corporate email format. The most frequently observed pattern is the first initial of the employee's first name followed by their full last name, all preceding '@iteostherapeutics.com'.

[first_initial][last]@iteostherapeutics.com

Format

jdoe@iteostherapeutics.com

Example

80%

Success rate

What's the Latest News About iTeos Therapeutics?

GlobeNewswire (via Yahoo Finance)May 9, 2024

iTeos Therapeutics SA Reports First Quarter 2024 Financial Results and Provides Business Update

iTeos announced its financial results for the first quarter of 2024, highlighting progress in its clinical programs for EOS-448 (belrestotug) and EOS-984, and outlined upcoming milestones....more

GlobeNewswireApril 8, 2024

iTeos Therapeutics SA Presents Encouraging New Data from Ongoing Phase 1/2 Trial of Belrestotug (EOS-448) in Combination with Pembrolizumab at AACR 2024

The company presented updated positive data from its Phase 1/2 trial of belrestotug in combination with pembrolizumab in patients with advanced solid tumors, demonstrating promising anti-tumor activity and a manageable safety profile....more

GlobeNewswire (via Yahoo Finance)February 28, 2024

iTeos Therapeutics SA Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

iTeos reported its financial results for Q4 and full year 2023, detailed advancements across its immuno-oncology pipeline, and discussed strategic priorities for 2024....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including iTeos Therapeutics, are just a search away.